Membranolytic peptide programs immunogenic cell death for cancer therapy.

Synthetic pH-responsive membranolytic peptide aMP C16-CA50 induces immunogenic cell death in tumor cells, enhancing immune checkpoint blockade therapy in mice.

• Why it matters: Facilitating new modes of tumor cell death can improve antitumor therapies, especially by boosting immune responses and overcoming resistance to existing treatments.
• What they did: Researchers designed and implemented a membranolytic peptide that activates a spatiotemporal membrane-rupture process in tumor cells, inducing inflammatory gene programs and antigen presentation, with systemic administration well tolerated in mice.
• The result: This approach significantly enhances the antitumor efficacy of immune checkpoint blockade therapy by promoting immune responses, demonstrating potential for programmable immunogenic cell death in cancer treatment.